91 related articles for article (PubMed ID: 23791157)
1. The Malthus Programme: developing radiotherapy demand models for breast and prostate cancer at the local, regional and national level.
Round C; Mee T; Kirkby NF; Cooper T; Williams MV; Jena R
Clin Oncol (R Coll Radiol); 2013 Sep; 25(9):538-45. PubMed ID: 23791157
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy demand and activity in England 2006-2020.
Round CE; Williams MV; Mee T; Kirkby NF; Cooper T; Hoskin P; Jena R
Clin Oncol (R Coll Radiol); 2013 Sep; 25(9):522-30. PubMed ID: 23768454
[TBL] [Abstract][Full Text] [Related]
3. Quantifying uncertainty in radiotherapy demand at the local and national level using the Malthus model.
Jena R; Mee T; Kirkby NF; Williams MV
Clin Oncol (R Coll Radiol); 2015 Feb; 27(2):92-8. PubMed ID: 25500188
[TBL] [Abstract][Full Text] [Related]
4. Geographical variation in radiotherapy services across the UK in 2007 and the effect of deprivation.
Williams MV; Drinkwater KJ
Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):431-40. PubMed ID: 19560908
[TBL] [Abstract][Full Text] [Related]
5. Variations in Demand across England for the Magnetic Resonance-Linac Technology, Simulated Utilising Local-level Demographic and Cancer Data in the Malthus Project.
Mee T; Vickers AJ; Jena R; Kirkby KJ; Choudhury A; Kirkby NF
Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e285-e294. PubMed ID: 33775495
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy in England in 2007: modelled demand and audited activity.
Williams MV; Drinkwater KJ
Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):575-90. PubMed ID: 19651499
[TBL] [Abstract][Full Text] [Related]
7. An Update to the Malthus Model for Radiotherapy Utilisation in England.
Heritage S; Sundaram S; Kirkby NF; Kirkby KJ; Mee T; Jena R
Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e1-e9. PubMed ID: 35835634
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
9. The changing costs of radiation treatment for early prostate cancer in Ontario: a comparison between conventional and conformal external beam radiotherapy.
Poon I; Pintilie M; Potvin M; McGowan T
Can J Urol; 2004 Feb; 11(1):2125-32. PubMed ID: 15003151
[TBL] [Abstract][Full Text] [Related]
10. A prospective survey of radiotherapy in Sweden.
Acta Oncol; 1996; 35 Suppl 6():47-56. PubMed ID: 9154085
[TBL] [Abstract][Full Text] [Related]
11. Defining the need for prostate cancer radiotherapy in the general population: a criterion-based benchmarking approach.
Kerba M; Miao Q; Zhang-Salomons J; Mackillop W
Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):801-9. PubMed ID: 20797840
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy dose fractionation, access and waiting times in the countries of the UK in 2005.
Williams MV; Summers ET; Drinkwater K; Barrett A
Clin Oncol (R Coll Radiol); 2007 Jun; 19(5):273-86. PubMed ID: 17517327
[TBL] [Abstract][Full Text] [Related]
13. Estimation of the optimal number of radiotherapy fractions for breast cancer: A review of the evidence.
Wong K; Delaney GP; Barton MB
Radiother Oncol; 2015 Aug; 116(2):174-8. PubMed ID: 26272649
[TBL] [Abstract][Full Text] [Related]
14. Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer.
Strigari L; Arcangeli G; Arcangeli S; Benassi M
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1454-60. PubMed ID: 18990503
[TBL] [Abstract][Full Text] [Related]
15. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
16. Estimating the need for radiotherapy for patients with prostate, breast, and lung cancers: verification of model estimates of need with radiotherapy utilization data from British Columbia.
Tyldesley S; Delaney G; Foroudi F; Barbera L; Kerba M; Mackillop W
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1507-15. PubMed ID: 20605338
[TBL] [Abstract][Full Text] [Related]
17. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
[TBL] [Abstract][Full Text] [Related]
18. What will be the radiotherapy machine capacity required for optimal delivery of radiotherapy in Scotland in 2015?
Erridge SC; Featherstone C; Chalmers R; Campbell J; Stockton D; Black R
Eur J Cancer; 2007 Aug; 43(12):1802-9. PubMed ID: 17616389
[TBL] [Abstract][Full Text] [Related]
19. Utilisation of radiotherapy in rural and urban areas in British Columbia compared with evidence-based estimates of radiotherapy needs for patients with breast, prostate and lung cancer.
Tyldesley S; McGahan C
Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):526-32. PubMed ID: 20594811
[TBL] [Abstract][Full Text] [Related]
20. [Trends in the use of primary radiotherapy for cancer in the Netherlands in patients with breast, prostate, rectal and lung tumours].
Struikmans H; Aarts MJ; Jobsen JJ; Koning CC; Poortmans PM; Louwman MW; Coebergh JW
Ned Tijdschr Geneeskd; 2012; 156(12):A4426. PubMed ID: 22436526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
